Integrated safety analysis of anti-programmed cell death-1 (PD-1) antibody penpulimab in advanced solid tumour or lymphoma

被引：0
|
作者：
Xu, N. [1 ]
Han, B. [2 ]
Jiao, S. [3 ]
Hu, C. [4 ]
Mislang, A. [5 ]
Coward, J. [6 ]
Cooper, A. [7 ]
Underhill, C. [8 ]
Xia, Y. [9 ]
Xia, D. [9 ]
Jin, X. [9 ]
Wang, Z. M. [9 ]
Li, B. [9 ]
机构：
[1] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Oncol, Hangzhou, Peoples R China
[2] Shanghai Chest Hosp, Dept Oncol, Shanghai, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing, Peoples R China
[4] Shanghai Canc Ctr, Dept Radiotherapy, Shanghai, Peoples R China
[5] Adelaide Canc Ctr, Dept Oncol, Kurralta Pk, Australia
[6] Icon Canc Ctr, Dept Oncol, Brisbane, Qld, Australia
[7] Univ Western Sydney, Sch Med, Dept Oncol, Liverpool, Australia
[8] Albury Wodonga Reg Canc Ctr, Dept Oncol, Albury, NSW, Australia
[9] Akeso Biopharma Inc, Zhongshan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.518
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
31P
引用
收藏
页码：S1428 / S1429
页数：2
相关论文
共 50 条
  • [1] A PHASE II STUDY OF THE ANTI-PROGRAMMED CELL DEATH-1 (PD-1) ANTIBODY PENPULIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSIC HODGKIN LYMPHOMA (CHL)
    Song, Yuqin
    Zhou, Keshu
    Jin, Chuan
    Qian, Zhengzi
    Hou, Ming
    Fan, Lei
    Li, Fei
    Ding, Kaiyang
    Zhou, Hui
    Li, Xiaoling
    Chen, Bing
    Sun, Xiuhua
    Song, Xianmin
    Jiang, Ming
    Zhang, Qingyuan
    Liu, Lihong
    Yu, Guohua
    Hu, Yu
    Zhao, Zheng
    Liu, Ligen
    Xue, Hongwei
    Luo, Jun
    He, Bai
    Jin, Xiaoping
    Wang, Maxwell
    Li, Baiyong
    Xia, Yu
    Zhu, Jun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A473 - A474
  • [2] Efficacy and safety of penpulimab (AK105), a new generation anti-programmed cell death-1 (PD-1) antibody, in upper gastrointestinal cancers
    Mislang, A. R. A.
    Coward, J.
    Cooper, A.
    Underhill, C. R.
    Zheng, Y.
    Xu, N.
    Xiao, C.
    Jin, X.
    Li, B.
    Wang, M.
    Kwek, K. Y.
    Xia, D.
    Xia, Y.
    Prawira, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1300 - S1301
  • [3] Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers
    Rajan, Arun
    Kim, Chul
    Heery, Christopher R.
    Guha, Udayan
    Gulley, James L.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (09) : 2219 - 2231
  • [4] Anti-Programmed Cell Death-1 (PD-1) Monoclonal Antibodies in Treating Advanced Melanoma
    Metcalfe, Whitney
    Anderson, Jaime
    Van Anh Trinh
    Hwu, Wen-Jen
    DISCOVERY MEDICINE, 2015, 19 (106) : 393 - 401
  • [5] Anti-Programmed Cell Death-1 (PD-1) Monoclonal Antibodies in Treating Advanced Melanoma - A Clinical Update
    Van Anh Trinh
    Joseph, Jocelyn
    Hwu, Wen-Jen
    DISCOVERY MEDICINE, 2018, 25 (135) : 31 - 40
  • [6] An Anti-Programmed Death-1 Antibody (αPD-1) Fusion Protein That Self-Assembles into a Multivalent and Functional αPD-1 Nanoparticle
    Zhao, Peng
    Atanackovic, Djordje
    Dong, Shuyun
    Yagita, Hideo
    He, Xiao
    Chen, Mingnan
    MOLECULAR PHARMACEUTICS, 2017, 14 (05) : 1494 - 1500
  • [7] Kidney retransplantation after anti-programmed cell death-1 (PD-1)-related allograft rejection
    Lipson, Evan J.
    Naqvi, Fizza F.
    Loss, Manisha J.
    Schollenberger, Megan D.
    Pardoll, Drew M.
    Moore, Jack, Jr.
    Brennan, Daniel C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 (08) : 2264 - 2268
  • [8] Anti-programmed cell death-1 (PD-1) monoclonal antibodies involve reversible cranial dura matter
    Kataoka, Hiroshi
    Shimada, Daisuke
    Nanaura, Hitoki
    Sugie, Kazuma
    OXFORD MEDICAL CASE REPORTS, 2021, (09): : 330 - 332
  • [9] NIVOLUMAB (ANTI-PROGRAMMED DEATH-1 [PD-1]; BMS-936558) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS: CLINICAL ACTIVITY, SAFETY, AND MOLECULAR MARKERS
    Feltquate, D. M.
    ANNALS OF ONCOLOGY, 2013, 24 : 7 - 7
  • [10] Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma
    Lee, Joycelyn J. X.
    Chan, Alexandre
    Tang, Tiffany
    ACTA ONCOLOGICA, 2016, 55 (04) : 519 - 520
12345